Wikipedia

David E. Olson

(Redirected from Draft:David E. Olson)

David E. Olson is an American chemist and neuroscientist. He is an associate professor of chemistry, biochemistry and molecular medicine at the University of California, Davis,[1][2][3] and is the founding director of the UC Davis Institute for Psychedelics and Neurotherapeutics.[4]

David E. Olson
NationalityAmerican
Alma materUnion College, Stanford University, Broad Institute of MIT and Harvard
Occupation(s)Chemical Neuroscientist, Professor, Entrepreneur
Employer(s)University of California, Davis; Delix Therapeutics
Known forDiscovery of neuroplasticity promoting effects of psychedelics
WebsiteOlsonlab.org

Olson is best known for his work investigating neuroplasticity promoting compounds, especially the potential of psychedelic drugs, including ketamine and serotonergic psychedelics, to alter brain structure and function. Olson also coined a term to refer to small molecules that are fast acting, durable neuroplasticity promoting compounds: psychoplastogens. Psychoplastogens are being developed to treat a wide variety of neuropsychiatric and neurodegenerative diseases, including depression, PTSD, and substance use disorders, among many others.[5][6]

Early life

edit

Olson received his B.S. from Union College in 2006 with a major in chemistry and a minor in biology.

He then worked briefly at Albany Molecular Research Inc. before completing a Ph.D. in chemistry at Stanford University in 2011, where he worked in the laboratory of Justin Du Bois, developing a variety of methods for synthesizing nitrogen-containing compounds.[7]

Olson undertook postdoctoral research in neuroscience at the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard where he focused on the therapeutic potential of HDAC inhibitors.[8]

Career

edit

In 2015 Olson started his independent career at the University of California, Davis, with a joint appointment in the department of chemistry (college of letters and science) and the department of biochemistry and molecular medicine (school of medicine).[1] He is also an affiliate member of the Center for Neuroscience and the UC Davis Memory and Plasticity Program.[9] In 2021, Olson was promoted to associate professor with tenure. In 2019, Olson co-founded Delix Therapeutics—a biotech company focused on developing novel neuroplasticity-promoting therapeutics for central nervous system diseases (CNS).[10] Olson served as the company's chief scientific officer until 2021, when he transitioned to the roles of chief innovation officer and head of the scientific advisory board.[11]

Awards

edit
  • 2023 Mahoney Institute for Neurosciences (MINS) Rising Star Award[12][13]
  • 2023 UC Davis Chancellor’s Fellow[14]
  • 2022 Sacramento Business Journal's 40 Under 40[15]
  • 2021 Sigma Xi Young Investigator Award[16]
  • 2021 Camille Dreyfus Teacher-Scholar[17]
  • 2021 Life Young Investigator Award[18]
  • 2020 Jordi Folch-Pi Award from the American Society for Neurochemistry[19]

Other activities

edit

Currently, he serves on the editorial advisory boards of the journals ACS Chemical Neuroscience[20] and ACS Pharmacology & Translational Science.[21]

Published works

edit

Olson has published numerous scientific publications.[22] Several of his key contributions to the field are cited below:

  • Vargas, Maxemiliano V.; Dunlap, Lee E.; Dong, Chunyang; Carter, Samuel J.; Tombari, Robert J.; Jami, Shekib A.; Cameron, Lindsay P.; Patel, Seona D.; Hennessey, Joseph J.; Saeger, Hannah N.; McCorvy, John D.; Gray, John A.; Tian, Lin; Olson, David E. (17 February 2023). "Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors". Science. 379 (6633): 700–706. Bibcode:2023Sci...379..700V. doi:10.1126/science.adf0435. PMC 10108900. PMID 36795823. S2CID 256901481.
  • Dong, Chunyang; Ly, Calvin; Dunlap, Lee E.; Vargas, Maxemiliano V.; Sun, Junqing; Hwang, In-Wook; Azinfar, Arya; Oh, Won Chan; Wetsel, William C.; Olson, David E.; Tian, Lin (13 May 2021). "Psychedelic-inspired drug discovery using an engineered biosensor". Cell. 184 (10): 2779–2792.e18. doi:10.1016/j.cell.2021.03.043. PMC 8122087. PMID 33915107.
  • Cameron, Lindsay P.; Tombari, Robert J.; Lu, Ju; Pell, Alexander J.; Hurley, Zefan Q.; Ehinger, Yann; Vargas, Maxemiliano V.; McCarroll, Matthew N.; Taylor, Jack C.; Myers-Turnbull, Douglas; Liu, Taohui; Yaghoobi, Bianca; Laskowski, Lauren J.; Anderson, Emilie I.; Zhang, Guoliang; Viswanathan, Jayashri; Brown, Brandon M.; Tjia, Michelle; Dunlap, Lee E.; Rabow, Zachary T.; Fiehn, Oliver; Wulff, Heike; McCorvy, John D.; Lein, Pamela J.; Kokel, David; Ron, Dorit; Peters, Jamie; Zuo, Yi; Olson, David E. (January 2021). "A non-hallucinogenic psychedelic analogue with therapeutic potential". Nature. 589 (7842): 474–479. Bibcode:2021Natur.589..474C. doi:10.1038/s41586-020-3008-z. PMC 7874389. PMID 33299186.
  • Dunlap, Lee E.; Azinfar, Arya; Ly, Calvin; Cameron, Lindsay P.; Viswanathan, Jayashri; Tombari, Robert J.; Myers-Turnbull, Douglas; Taylor, Jack C.; Grodzki, Ana Cristina; Lein, Pamela J.; Kokel, David; Olson, David E. (13 February 2020). "Identification of Psychoplastogenic N , N -Dimethylaminoisotryptamine (isoDMT) Analogues through Structure–Activity Relationship Studies". Journal of Medicinal Chemistry. 63 (3): 1142–1155. doi:10.1021/acs.jmedchem.9b01404. PMC 7075704. PMID 31977208.
  • Cameron, Lindsay P.; Benson, Charlie J.; DeFelice, Brian C.; Fiehn, Oliver; Olson, David E. (17 July 2019). "Chronic, Intermittent Microdoses of the Psychedelic N , N -Dimethyltryptamine (DMT) Produce Positive Effects on Mood and Anxiety in Rodents". ACS Chemical Neuroscience. 10 (7): 3261–3270. doi:10.1021/acschemneuro.8b00692. PMC 6639775. PMID 30829033.
  • Ly, Calvin; Greb, Alexandra C.; Cameron, Lindsay P.; Wong, Jonathan M.; Barragan, Eden V.; Wilson, Paige C.; Burbach, Kyle F.; Soltanzadeh Zarandi, Sina; Sood, Alexander; Paddy, Michael R.; Duim, Whitney C.; Dennis, Megan Y.; McAllister, A. Kimberley; Ori-McKenney, Kassandra M.; Gray, John A.; Olson, David E. (12 June 2018). "Psychedelics Promote Structural and Functional Neural Plasticity". Cell Reports. 23 (11): 3170–3182. doi:10.1016/j.celrep.2018.05.022. PMC 6082376. PMID 29898390.

References

edit
  1. ^ a b Marrush, Najwa (2017-07-27). "David E. Olson, Ph.D." UC Davis Center for Neuroscience. Retrieved 2022-08-30.
  2. ^ "David E. Olson | Chemistry". 13 June 2017.
  3. ^ "David E. Olson, Ph.D. | UC Davis Department of Biochemistry and Molecular Medicine".
  4. ^ "Institute for Psychedelics and Neurotherapeutics". neurotherapeutics.ucdavis.edu.
  5. ^ Yakowicz, Will. "Delix Therapeutics Pursues A Psychedelic-Inspired Medicine Without The Trip". Forbes. Retrieved 2022-08-30.
  6. ^ Smith, Dana G. (2022-07-15). "Opinion | Taking the Magic Out of Magic Mushrooms". The New York Times. ISSN 0362-4331. Retrieved 2022-08-30.
  7. ^ Olson, David E.; Maruniak, Autumn; Malhotra, Sushant; Trost, Barry M.; Du Bois, J. (July 2011). "Synthesis and Reactivity of Unique Heterocyclic Structures en Route to Substituted Diamines". Organic Letters. 13 (13): 3336–3339. doi:10.1021/ol2010769. PMC 3123413. PMID 21618989.[non-primary source needed]
  8. ^ Olson, David E.; Sleiman, Sama F.; Bourassa, Megan W.; Wagner, Florence F.; Gale, Jennifer P.; Zhang, Yan-Ling; Ratan, Rajiv R.; Holson, Edward B. (April 2015). "Hydroxamate-Based Histone Deacetylase Inhibitors Can Protect Neurons from Oxidative Stress via a Histone Deacetylase-Independent Catalase-Like Mechanism". Chemistry & Biology. 22 (4): 439–445. doi:10.1016/j.chembiol.2015.03.014. PMC 4562013. PMID 25892200.[non-primary source needed]
  9. ^ "Leadership". UC DAVIS MEMORY AND PLASTICITY PROGRAM. Retrieved 2021-08-27.
  10. ^ Yakowicz, Will. "Delix Therapeutics Pursues A Psychedelic-Inspired Medicine Without The Trip". Forbes. Retrieved 2022-06-09.
  11. ^ LaHucik, Kyle (2021-09-27). "Delix raises $70M to test psychedelic analogs for treating brain disorders in clinical trials next year". Fierce Biotech. Retrieved 2022-08-30.
  12. ^ "38th Annual MINS Symposium – Year of Psychedelics – Center for Neuroscience & Society".
  13. ^ "David Olson Receives Rising Star Award in Neurobiology of Psychedelics | UC Davis College of Letters and Science". 5 May 2023.
  14. ^ "13 Honored as Chancellor's Fellows". 14 February 2023.
  15. ^ https://www.bizjournals.com/sacramento/news/2022/11/11/40-under-40-david-olson-delix.html [bare URL]
  16. ^ "David Olson".
  17. ^ "2021 Camille Dreyfus Teacher-Scholar Awards". 30 April 2021.
  18. ^ "Life".
  19. ^ "American Society for Neurochemistry - Recipients of the Jordi Folch-Pi Award".
  20. ^ "Editorial Board". pubs.acs.org. Retrieved 2022-06-15.
  21. ^ "Editorial Board". pubs.acs.org. Retrieved 2022-06-15.
  22. ^ Search Results for author Olson DE on PubMed.
Retrieved from "https://en.wikipedia.org/w/index.php?title=David_E._Olson&oldid=1246310211"